Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POST-CARE trial
2024-515333-14-00Phase 3Withdrawn
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cancer comparing Ketorolac + Mediterranean diet + low-dose aspirin with Placebo/standard perioperative management (2 arms). Primary endpoint: 90-day surgery-related severe morbidity. Planned start Feb 2025; status: withdrawn.
02
Drugs
ketorolacaspirin
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-515333-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515333-14-00.